
Xtant Medical Holdings, Inc.: shareholders and insiders
Price
$0.21
November 16, 2026Market cap $29M
What Ploutos Investor adds for Xtant Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 34% since Aug 11, 2026, when the 10-Q these figures come from was filed ($0.32 then, $0.21 on Nov 16, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Aug 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
–
nobody
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
No trades under these filters.
From the Form 4s insiders file with the SEC within two business days of each trade.
Insiders and their shares
Every buy and sale by XTNT's officers and directors from 2011 up to November 16, 2025, 15 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 10 more, back to 2011
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Nantahala Capital Partners Limited Partnershipwith 3 more personsShare of class49.1%
- Lytton Laurence Wwith 1 more personShare of class5.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Nantahala Capital Partners Limited Partnershipwith 3 more persons | 49.1% | 68.39M | Aug 5, 20253 filings since Nov 14, 2024 | 13D/A | |
| Lytton Laurence Wwith 1 more person | 5.50% | 7.70M | Feb 17, 20262 filings since Apr 16, 2025 | 13G/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Nantahala Capital Partners Limited Partnership49.1%From the filing of Aug 5, 2025
Item 4 is amended by the addition of the following: On August 1, 2025, the Board of Directors (the "Board") of the Issuer elected Abhinav (Abi) Jain, an Analyst at NCM, to the Board. Mr. Jain was appointed to serve as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board. Mr. Jain's appointment was described further by the Issuer in a Form 8-K filed with the SEC on August 4, 2025.
From the filing of Aug 5, 2025
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Orbimed Advisors13D0.00%Apr 14, 202513D/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+19%
- Millennium Mgmt (Englander)In the quarter-36%
- Renaissance TechnologiesIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 191.4K | +19% | $100.0K | 0.00% |
| Millennium Mgmt (Englander) | 84.5K | -36% | $0 | 0.00% |
| Renaissance Technologies | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 0.21% of its shares outstanding were held short, +109.3% since the report before.
- Shares held short
- 300.5K
- 0.21%
- Since the report before143.6K on Sep 30, 2026
- +109.3%
- 3.3
- 92.2K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 38%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 340.1K
- Nov 15, 2023: Shares held short 331.1K
- Nov 30, 2023: Shares held short 311.3K
- Dec 15, 2023: Shares held short 261.9K
- Dec 29, 2023: Shares held short 253.5K
- Jan 12, 2024: Shares held short 177.4K
- Jan 31, 2024: Shares held short 168.2K
- Feb 15, 2024: Shares held short 221.7K
- Feb 29, 2024: Shares held short 172.8K
- Mar 15, 2024: Shares held short 192.5K
- Mar 28, 2024: Shares held short 280.6K
- Apr 15, 2024: Shares held short 260.9K
- Apr 30, 2024: Shares held short 275.6K
- May 15, 2024: Shares held short 226.8K
- May 31, 2024: Shares held short 212.5K
- Jun 14, 2024: Shares held short 208.9K
- Jun 28, 2024: Shares held short 194.6K
- Jul 15, 2024: Shares held short 190.0K
- Jul 31, 2024: Shares held short 174.0K
- Aug 15, 2024: Shares held short 213.0K
- Aug 30, 2024: Shares held short 213.6K
- Sep 13, 2024: Shares held short 192.4K
- Sep 30, 2024: Shares held short 231.8K
- Oct 15, 2024: Shares held short 215.7K
- Oct 31, 2024: Shares held short 197.5K
- Nov 15, 2024: Shares held short 246.9K
- Nov 29, 2024: Shares held short 36.3K
- Dec 13, 2024: Shares held short 26.9K
- Dec 31, 2024: Shares held short 114.8K
- Jan 15, 2025: Shares held short 177.5K
- Jan 31, 2025: Shares held short 105.7K
- Feb 14, 2025: Shares held short 91.3K
- Feb 28, 2025: Shares held short 89.8K
- Mar 14, 2025: Shares held short 64.7K
- Mar 31, 2025: Shares held short 61.7K
- Apr 15, 2025: Shares held short 66.3K
- Apr 30, 2025: Shares held short 59.9K
- May 15, 2025: Shares held short 43.9K
- May 30, 2025: Shares held short 24.2K
- Jun 13, 2025: Shares held short 56.5K
- Jun 30, 2025: Shares held short 62.1K
- Jul 15, 2025: Shares held short 23.0K
- Jul 31, 2025: Shares held short 30.9K
- Aug 15, 2025: Shares held short 36.9K
- Aug 29, 2025: Shares held short 42.9K
- Sep 15, 2025: Shares held short 62.2K
- Sep 30, 2025: Shares held short 42.9K
- Oct 15, 2025: Shares held short 104.3K
- Oct 31, 2025: Shares held short 79.8K
- Nov 14, 2025: Shares held short 13.7K
- Nov 28, 2025: Shares held short 19.3K
- Dec 15, 2025: Shares held short 74.4K
- Dec 31, 2025: Shares held short 33.1K
- Jan 15, 2026: Shares held short 24.7K
- Jan 30, 2026: Shares held short 20.7K
- Feb 13, 2026: Shares held short 28.1K
- Feb 27, 2026: Shares held short 18.0K
- Mar 13, 2026: Shares held short 23.2K
- Mar 31, 2026: Shares held short 39.7K
- Apr 15, 2026: Shares held short 12.8K
- Apr 30, 2026: Shares held short 70.5K
- May 15, 2026: Shares held short 19.5K
- May 29, 2026: Shares held short 3,862
- Jun 15, 2026: Shares held short 1,568
- Jun 30, 2026: Shares held short 3,245
- Jul 15, 2026: Shares held short 70.0K
- Jul 31, 2026: Shares held short 89.0K
- Aug 14, 2026: Shares held short 103.4K
- Aug 31, 2026: Shares held short 1.83M
- Sep 15, 2026: Shares held short 268.7K
- Sep 30, 2026: Shares held short 143.6K
- Oct 15, 2026: Shares held short 300.5K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading29.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 29.1% of the shares in the reported trades were short sales, against 51.6% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 29.1%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 51.6%
- Change
- -22.5 pts
- Short sales a dayon average, of 166.9K shares
- 48.6K
- More than atof 3,668 US-listed companies, same days
- 4%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 48.5%
- Oct 9, 2026: Short sales 69.1%
- Oct 12, 2026: Short sales 70.8%
- Oct 13, 2026: Short sales 42.9%
- Oct 14, 2026: Short sales 3.7%
- Oct 15, 2026: Short sales 14.4%
- Oct 16, 2026: Short sales 67.5%
- Oct 19, 2026: Short sales 65.9%
- Oct 20, 2026: Short sales 70.1%
- Oct 21, 2026: Short sales 48.8%
- Oct 22, 2026: Short sales 48%
- Oct 23, 2026: Short sales 23.1%
- Oct 26, 2026: Short sales 32.6%
- Oct 27, 2026: Short sales 79.1%
- Oct 28, 2026: Short sales 71.1%
- Oct 29, 2026: Short sales 18.7%
- Oct 30, 2026: Short sales 31.3%
- Nov 2, 2026: Short sales 20%
- Nov 3, 2026: Short sales 50.7%
- Nov 4, 2026: Short sales 61.8%
- Nov 5, 2026: Short sales 45.4%
- Nov 6, 2026: Short sales 33%
- Nov 9, 2026: Short sales 45.3%
- Nov 10, 2026: Short sales 1.9%
- Nov 11, 2026: Short sales 44.5%
- Nov 12, 2026: Short sales 58%
- Nov 13, 2026: Short sales 35.1%
- Nov 16, 2026: Short sales 33.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Stavros G. VizirgianakisDirectorDirectly7.84M
- Sean E BrownePresident and CEODirectly3.11M
- Jonn R. BeesonDirectorDirectly1.75M
- Scott C NeilsCFO and Assistant SecretaryDirectly1.22M
- John K BakewellDirectorDirectly1.13M
- Mark A. SchallenbergerChief Operating OfficerDirectly1.11M
- Tyler LipschultzDirectorDirectly373.7K
- Abhinav JainDirectorDirectly373.7K
- Orbimed ROF II LLCTenPercentOwnerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Stavros G. VizirgianakisDirector | 7.84M | – | Aug 15, 2026 | Form 4 |
| Sean E BrownePresident and CEO | 3.11M | – | Aug 15, 2026 | Form 4 |
| Jonn R. BeesonDirector | 1.75M | – | Aug 15, 2026 | Form 4 |
| Scott C NeilsCFO and Assistant Secretary | 1.22M | – | Aug 15, 2026 | Form 4 |
| John K BakewellDirector | 1.13M | – | Aug 15, 2026 | Form 4 |
| Mark A. SchallenbergerChief Operating Officer | 1.11M | – | Aug 15, 2026 | Form 4 |
| Tyler LipschultzDirector | 373.7K | – | Aug 15, 2026 | Form 4 |
| Abhinav JainDirector | 373.7K | – | Aug 15, 2026 | Form 4 |
| Orbimed ROF II LLCTenPercentOwner | – | – | Apr 10, 2025 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
1 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 30
- Q4 2025: Managers 35
- Q1 2026: Managers 34
- Q2 2026: Managers 32
Institutional investors by quarter
The fund managers holding XTNT, quarter by quarter, from Q3 2015 to Q2 2025, 40 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 32 managers held 149M shares, worth $63M. During the quarter 5 opened a position, 7 closed one, 7 added and 3 trimmed.
The largest holders, Q2 2026
- Nantahala Capital ManagementIn the quarter+100%
- AWM InvestmentIn the quarter
- Vanguard Capital ManagementIn the quarter
- Renaissance TechnologiesIn the quarter-5.3%
- Geode Capital ManagementIn the quarter-2.3%
- Crescent Grove AdvisorsIn the quarter
- Nano Cap New Millennium Growth Fund L PIn the quarter+14%
- Vanguard Fiduciary TrustIn the quarter
- Citadel Advisors (Griffin)In the quarter+19%
- Acadian Asset ManagementIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Nantahala Capital Management | 137M | +100% | $58M |
| AWM Investment | 5.98M | $2.5M | |
| Vanguard Capital Management | 2.01M | $848.1K | |
| Renaissance Technologies | 935.1K | -5.3% | $393.7K |
| Geode Capital Management | 517.1K | -2.3% | $217.8K |
| Crescent Grove Advisors | 412.0K | $173.5K | |
| Nano Cap New Millennium Growth Fund L P | 400.0K | +14% | $168.4K |
| Vanguard Fiduciary Trust | 258.0K | $108.6K | |
| Citadel Advisors (Griffin) | 191.4K | +19% | $80.6K |
| Acadian Asset Management | 180.3K | $73.0K |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Xtant Medical's filings show?
Who buys and sells is one part of Xtant Medical's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have XTNT's insiders bought or sold?
From Aug 18, 2026 to Aug 18, 2026 Xtant Medical's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold XTNT?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $100.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.